Clinical Trial Update: A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics, and immunogenicity of HuL001 in idiopathic pulmonary fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• HuL001

Snippet

Sponsor: HuniLife Biotechnology, Inc. | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: COMPLETED